Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „substrates“
Suchtreffer
Begriffe & Kennungen
Harvoni · 4.5 · Ledipasvir and sofosbuvir are substrates of drug transporter P-gp and BCRP while GS-331007 is not.
Eintrag öffnenHarvoni · 4.5 · Ledipasvir and sofosbuvir are substrates of drug transporter P-gp and BCRP while GS-331007 is not.
Eintrag öffnenHepcludex · 4.5 · 4 As a precautionary measure, close clinical monitoring is warranted when NTCP substrates (e.g. estrone-3-sulf
Eintrag öffnenIbrance · 4.5 · 8 transporter OCT1 and then may increase the exposure of medical product substrates of this transporter (e.g.,
Eintrag öffnenIbrance · 4.5 · Concomitant use of palbociclib with statins which are substrates of CYP3A4 and/or BCRP may increase the risk o
Eintrag öffnenIbrance · 4.5 · Concomitant use of palbociclib with statins which are substrates of CYP3A4 and/or BCRP may increase the risk o
Eintrag öffnenIbrance · 4.5 · The dose of sensitive CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydr
Eintrag öffnenIbrance · 4.5 · The dose of sensitive CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydr
Eintrag öffnenIclusig · 4.5 · Transporter substrates In vitro, ponatinib is an inhibitor of P-gp and BCRP. Therefore, ponatinib may have the
Eintrag öffnenIclusig · 4.5 · Transporter substrates In vitro, ponatinib is an inhibitor of P-gp and BCRP. Therefore, ponatinib may have the
Eintrag öffnenInaqovi · 4.5 · Decitabine and cedazuridine are not substrates or inhibitors for cytochrome P450 (CYP450); thus interactions w
Eintrag öffnenIqirvo · 4.5 · CYP2C9 substrates (Warfarin):
Eintrag öffnenIqirvo · 4.5 · CYP3A4 substrates Based on clinical studies conducted , elafibranor may be a mild CYP3A4 inducer. A clinical i
Eintrag öffnenJavlor · 4.5 · A possible interaction with paclitaxel and docetaxel (CYP3 substrates) has been suggested from an in vitro stu
Eintrag öffnenJaypirca · 4.5 · 5 P-gp substrates Pirtobrutinib is a weak inhibitor of P-gp. Pirtobrutinib increased the AUC and Cmax of digox
Eintrag öffnenJaypirca · 4.5 · BCRP substrates Pirtobrutinib is a moderate inhibitor of BCRP. Pirtobrutinib increased the AUC and Cmax of ros
Eintrag öffnenJaypirca · 4.5 · CYP2C19 substrates Pirtobrutinib is a weak inhibitor of CYP2C19. Pirtobrutinib increased the AUC and Cmax of o
Eintrag öffnenJaypirca · 4.5 · CYP2C8 substrates Pirtobrutinib is a moderate inhibitor of CYP2C8. Pirtobrutinib increased the AUC and Cmax of
Eintrag öffnenJaypirca · 4.5 · CYP3A substrates Pirtobrutinib is a weak inhibitor of CYP3A. Pirtobrutinib increased the AUC and Cmax of orall
Eintrag öffnenJemperli · 4.5 · No interaction studies have been performed. Monoclonal antibodies (mAb) such as dostarlimab are not substrates
Eintrag öffnen